Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Corcept Therapeutics Inc has a consensus price target of $45.13 based on the ratings of 8 analysts. The high is $78 issued by Canaccord Genuity on July 31, 2024. The low is $22 issued by Jefferies on February 15, 2023. The 3 most-recent analyst ratings were released by Piper Sandler, Canaccord Genuity, and Canaccord Genuity on September 18, 2024, July 31, 2024, and July 30, 2024, respectively. With an average price target of $61 between Piper Sandler, Canaccord Genuity, and Canaccord Genuity, there's an implied 47.75% upside for Corcept Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Corcept Therapeutics (NASDAQ:CORT) was reported by Piper Sandler on September 18, 2024. The analyst firm set a price target for $67.00 expecting CORT to rise to within 12 months (a possible 62.29% upside). 18 analyst firms have reported ratings in the last year.
The latest analyst rating for Corcept Therapeutics (NASDAQ:CORT) was provided by Piper Sandler, and Corcept Therapeutics maintained their overweight rating.
The last upgrade for Corcept Therapeutics Inc happened on November 6, 2023 when Truist Securities raised their price target to $38. Truist Securities previously had a hold for Corcept Therapeutics Inc.
The last downgrade for Corcept Therapeutics Inc happened on February 15, 2023 when Jefferies changed their price target from $35 to $22 for Corcept Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corcept Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corcept Therapeutics was filed on September 18, 2024 so you should expect the next rating to be made available sometime around September 18, 2025.
While ratings are subjective and will change, the latest Corcept Therapeutics (CORT) rating was a maintained with a price target of $38.00 to $67.00. The current price Corcept Therapeutics (CORT) is trading at is $41.29, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.